Pd-l1 analog fusion proteins for antigen specific immunotherapy and methods of use
AssigneeAkston Biosciences Corporation
InventorsTodd C. ZION, Thomas M. LANCASTER
Life of this patent
Estimating the term…
Abstract
The present disclosure provides recombinantly manufactured fusion proteins comprising a Programmed Death-Ligand 1 (PD-L1) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients as a treatment for cancers, tumors or other diseases associated with expression of the PD-L1 protein in dogs. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.
Claims14
A method of producing a fusion protein comprising a PD-L1 analog and an Fc fragment, said method comprising transiently transfecting a nucleic acid encoding for the fusion protein into a CHO cell, wherein the transfected CHO cell expresses the fusion protein, wherein the PD-L1 analog comprises the following sequence:
- (SEQ ID NO:
- 23)
- LIGYGGADYKRITLKVHAPYRNISQRISVDPVTSEHELMCQAEGYPEAEV
- IWTSSDHRVLSGKTTITNSNREEKLFNVTSTLNINATANEIFYCTFQRSG
- PEENNTAELVIPERLPVPASERTHFMILGPF.
A cell engineered to express a fusion protein comprising a PD-L1 analog and an Fc fragment, wherein the PD-L1 analog comprises the following sequence:
- (SEQ ID NO:
- 23)
- LIGYGGADYKRITLKVHAPYRNISQRISVDPVTSEHELMCQAEGYPEAEV
- IWTSSDHRVLSGKTTITNSNREEKLFNVTSTLNINATANEIFYCTFQRSG
- PEENNTAELVIPERLPVPASERTHFMILGPF.
A cDNA encoding a fusion protein comprising a PD-L1 analog and an Fc fragment, wherein the PD-L1 analog comprises the following sequence:
- (SEQ ID NO:
- 23)
- LIGYGGADYKRITLKVHAPYRNISQRISVDPVTSEHELMCQAEGYPEAEV
- IWTSSDHRVLSGKTTITNSNREEKLFNVTSTLNINATANEIFYCTFQRSG
- PEENNTAELVIPERLPVPASERTHFMILGPF.
Dependencies are inferred from the claim text.